Servier key figures
key figures
We help to drive therapeutic progress
As a global pharmaceutical Group, we help to drive therapeutic progress by investing close to 20% of revenue from brand-name medicines in R&D each year.
About Servier
35th
largest pharmaceutical group worldwide
2nd
largest French pharmaceutical group
20%
Close to 20% of revenue from brand-name medicines invested in R&D each year
60
Over 60 scientific partnerships and collaborations in 2023/2024
22,000
Over 22,000 employees
95.8%
of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France
140
international patient organizations collaborated with Servier in 2023/2024
Driving scientific and medical progress
3
therapeutic areas: oncology, cardiometabolism & venous diseases, neurology
34
projects in clinical development (including 11 new molecular entities) and 22 research projects (February 2025)
5th
leading pharmaceutical group in cardiology worldwide1
1st
leading pharmaceutical group in hypertension worldwide1
Global presence
140
Close to 140 countries where the Group’s medicines are distributed
14
production sites
6
research centers
3
hubs (North and South America, Europe, Asia-Pacific) with 15 International Centers for Therapeutic Research
Social responsibility
-42%
target of reduction in our greenhouse gas emissions on scopes 1&2 in 2030 compared to 2021/2022 3
48%
of the Group’s managers are women as of 2023/2024
4.33/5
overall engagement score achieved by the Servier Group2
Financial performance
€5.9
billion in revenue in 2023/2024
(including €4.5 billion for brand-name medicines and €1.4 billion for generic activities)
€ 1.3
billion in EBITDA in 2023/2024 or 22.2% of Group revenue
[1] IQVIA, Analytics Link / World 76 countries – MAT Q1-2024
[2] Source: annual engagement survey conducted with the Gallup Institute – 2024 Group results
[3] Scope 1 emissions represent emissions directly linked to Group operations. Scope 2 emissions are linked to the purchase of electricity and energy for heating or cooling